Pharmaceuticals

Kura Oncology's new AML drug, KOMZIFTI, sees rapid market uptake, strong financials, and an ambitious plan to reshape targeted cancer therapy.

Early data for zolucatetide shows it shrinks tumors in a rare genetic disease, cracking a long-undruggable cancer target and offering new hope.

A novel oral drug for Alzheimer's avoids a key side effect of current therapies, as its 'detangler' platform shows promise for Parkinson's and other diseases.

With a unique entry-blocking drug, Bioxytran targets COVID, flu, and RSV, moving toward a pivotal trial that could redefine antiviral treatment.

The new iPSC-derived sensory neurons offer a reproducible human model, aiming to fix the broken pipeline of pain research and accelerate new analgesics.

Backed by JLL Partners, new platform Talica aims to unify the fragmented but vital surface science market for aerospace, pharma, and other high-tech industries.

Biotech firm ImmunoScape partners with a top US cancer center for a novel trial, backed by a strategic investment from actor Leonardo DiCaprio.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Beyond the prescription pad, a new concierge program in Tucson integrates advanced diagnostics and lifestyle coaching to redefine sustainable weight management.

A new partnership automates data flow for 2,500+ research sites, promising near-perfect accuracy and faster drug development. Here’s how it works.

The wholesale distributor is integrating its offline supply chain with a B2B digital platform, aiming for massive growth in China's tech-driven health market.

Scientists have supercharged a compound from rice bran, creating a potent new weapon against cellular aging that could reshape the future of nutrition.

A new partnership aims to use light and AI to break bottlenecks in drug development, promising to make personalized medicine faster and more accessible.

Data shows Achieve Life Sciences' drug helps smokers quit, even after multiple failed attempts with other drugs, as a critical FDA decision looms.

After solving a key manufacturing flaw, CervoMed advances its promising dementia drug, neflamapimod, to a Phase 3 trial with an optimized dose.

With its lead drug for a rare blood cancer nearing European submission, Cellectar Biosciences advances its targeted radiotherapy platform on two fronts.

Amid a volatile market, Ligand presents its sustainable growth blueprint, powered by royalties and partnerships, to top investors this March.

A new UK facility, backed by government funds, will be the only one of its kind, aiming to accelerate drug development and boost domestic life sciences.

Theolytics secures a prestigious €8 million EU grant to advance its unique cancer-killing virus, offering new hope for hard-to-treat ovarian cancer.

A new patented drug, budiodarone, aims to treat atrial fibrillation in heart failure patients, a group with few safe options. Is this the future of care?